|
Post by mnkdfann on Dec 11, 2015 11:49:52 GMT -5
I am confused as to what this product is. According to wikipedia, the existing NovoLog is NovoLog Mix 70/30, a product which contains 30% insulin aspart and 70% insulin aspart protamine. So is the new product 100% insulin aspart? en.m.wikipedia.org/wiki/Insulin_aspart
|
|
|
Post by Jstokcton on Dec 11, 2015 11:54:04 GMT -5
Anyone know the pharmacokinetics?
|
|
|
Post by jpg on Dec 11, 2015 11:55:46 GMT -5
Fast in, slow out. Anyone have the feeling Novo is better at this than Sanofi?
|
|
|
Post by esstan2001 on Dec 11, 2015 12:01:30 GMT -5
Anyone know the pharmacokinetics? As just another hexamer, I'd venture to guess subtly different (faster) than any other injected prandial; but no where near the speed of afrezza. Peppy or msccguy can probably elaborate from a more chemistry-centric point of view as to the whys of the subtlety- Novo is not talking monomer-insulin, that is our key.
|
|
|
Post by oldfishtowner on Dec 11, 2015 15:09:41 GMT -5
www.ncbi.nlm.nih.gov/pubmed/25846340Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
Heise T1, Hövelmann U1, Brøndsted L2, Adrian CL2, Nosek L1, Haahr H2. Author information Abstract AIMS: To evaluate the pharmacokinetics and pharmacodynamics of faster-acting insulin aspart and insulin aspart in a randomized, single-centre, double-blind study. METHODS: Fifty-two patients with type 1 diabetes (mean age 40.3 years) received faster-acting insulin aspart, insulin aspart, or another faster aspart formulation (not selected for further development), each as a single 0.2 U/kg subcutaneous dose, under glucose-clamp conditions, in a three-way crossover design (3-12 days washout between dosing). RESULTS: Faster-acting insulin aspart had a faster onset of exposure compared with insulin aspart, shown by a 57% earlier onset of appearance [4.9 vs 11.2 min; ratio 0.43, 95% confidence interval (CI) 0.36; 0.51], a 35% earlier time to reach 50% maximum concentration (20.7 vs 31.6 min; ratio 0.65, 95% CI 0.59; 0.72) and a greater early exposure within 90 min after dosing. The greatest difference occurred during the first 15 min, when area under the serum insulin aspart curve was 4.5-fold greater with faster-acting insulin aspart than with insulin aspart. Both treatments had a similar time to maximum concentration, total exposure and maximum concentration. Faster-acting insulin aspart had a significantly greater glucose-lowering effect within 90 min after dosing [largest difference: area under the curve for the glucose infusion rate (AUC(GIR), 0-30 min) ratio 1.48, 95% CI 1.13; 2.02] and 17% earlier time to reach 50% maximum glucose infusion rate (38.3 vs 46.1 min; ratio 0.83, 95% CI 0.73; 0.94). The primary endpoint (AUC(GIR, 0-2 h)) was 10% greater for faster-acting insulin aspart, but did not reach statistical significance (ratio 1.10, 95% CI 1.00; 1.22). Both treatments had similar total and maximum glucose-lowering effects, indicating similar overall potency. CONCLUSIONS: Faster-acting insulin aspart was found to have earlier onset and higher early exposure than insulin aspart, and a greater early glucose-lowering effect, with similar potency. The full paper is available at onlinelibrary.wiley.com/doi/10.1111/dom.12468/full. The pk/pd profiles do not look much different than insulin aspart. Certainly not close to Afrezza, if this is the Novo candidate we are talking about.
|
|
|
Post by sweedee79 on Dec 12, 2015 13:49:11 GMT -5
finance.yahoo.com/news/novo-nordisk-files-faster-acting-213509808.htmlThese are the developments that increase frustration levels. Although it is still injected its apparently given after the start of the meal. Filed with both FDA and EU. It appears that it will be available in EU before Afrezza will. The silver lining may be that now there may be a product in which we can compare to. Injected vs inhaled. Any one familiar with this product to know if it has any significant benefits to reduction of fasting blood glucose? This doesn't sound much different than Apidra... another Hexamer Insulin .
www.apidra.com/hcp/rapid-acting-apidra.aspx#faster-onset
Apidra® helps control blood sugar at mealtime. Apidra® is the only mealtime insulin approved for you to take within 15 minutes before or within 20 minutes after starting a meal
Apidra is insulin glulisine.. sounds like the new Novo insulin is aspart... not much difference.. none are techosphere insulin human monomer..
www.ncbi.nlm.nih.gov/pubmed/21457066
SNY has both of the fastest acting insulins on the market as of now... Apidra and Afrezza .. And Apidra doesn't hold a candle to Afrezza
Apidra has been on the market for some time and still doesn't have great insurance coverage .. Novo will have the same obstacles with their rapid acting insulin....
I don't see this one as a threat... If someone comes with an insulin that is technosphere.. and/or is a monomer insulin... than I will be worried.. Afrezza is pretty darn perfect and hard to beat... IMO .. But I agree... SNY and MNKD need to get it in gear a bit faster.. lowering the price... education.... whatever it takes....
|
|
|
Post by mnkdfann on Dec 16, 2015 9:11:18 GMT -5
|
|